Enhanced sensitivity HP-gas MRI/PET Dual Modality Imaging for Alzheimer's disease detection.

用于阿尔茨海默病检测的增强灵敏度 HP 气体 MRI/PET 双模态成像。

• 批准号: 566561-2021
• 负责人: Reznik, Alla
• 金额: $ 16.76万
• 依托单位: Lakehead University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=721786
• 关键词: Enhanced; sensitivity; HP; gas; MRI

Medical imaging technologies play a crucial role in early diagnosis and management of a variety of diseases, aswell as in clinical research and drug development. Continued developments of medical imaging systems havevastly improved our ability to visualize body tissues and processes, enabling more accurate detection ofmedical conditions. However, recent trends for personalized medicine call for new approaches in precisiondiagnostics with organ-specific imaging tools customized for particular organs or diseases. Dual-modalityimaging is an integral part of this approach as it offers complimentary visual and quantitative information thatis based on aligned morphological and functional data and therefore provides the highest efficacy anddiagnostic capability.One of the biggest areas of impact is Alzheimer's Disease (AD) where precision imaging is required foraccurate identification of a combination of specific AD biomarkers. This holds a promise to predict the futuredevelopment of dementia in patients at risk and to enable the diagnosis of Alzheimer's pathology at the earlystages when available treatments are maximally effective. It is also of a high importance to stratify cohort ofpatients for clinical trials with AD modifying therapies and for clinical neuroscience research.The overarching goal of this proposal is to develop an imaging system that will combine brain-dedicatedPositron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) for precisionbiomarker-guided medicine in AD. The proposed PET/MRI system will have some unique advantages toimprove early and differential diagnosis of AD through combining the metabolic and molecular informationfrom PET and structural, functional information from MRI. The commercialization and clinical use of theproposed PET/MRI technology will overcome "one-size-fits-all" approach for AD detection, intervention andprevention, and will advance the field of AD management beyond the current standard of care in Canada, andglobally.

医学成像技术在多种疾病的早期诊断和治疗以及临床研究和药物开发中发挥着至关重要的作用。医学成像系统的不断发展极大地提高了我们可视化身体组织和过程的能力，从而能够更准确地检测医疗状况。然而，个性化医疗的最新趋势需要使用针对特定器官或疾病定制的器官特异性成像工具进行精确诊断的新方法。双模态成像是该方法不可或缺的一部分，因为它提供了基于一致的形态和功能数据的免费视觉和定量信息，因此提供了最高的功效和诊断能力。影响最大的领域之一是阿尔茨海默病 (AD)，其中精确度需要成像来准确识别特定 AD 生物标志物的组合。这有望预测有风险的患者未来痴呆症的发展，并在现有治疗最有效的早期阶段诊断出阿尔茨海默氏症的病理学。对 AD 修饰疗法临床试验和临床神经科学研究的患者队列进行分层也非常重要。该提案的总体目标是开发一种将大脑专用正电子发射断层扫描 (PET) 与磁共振相结合的成像系统用于 AD 精准生物标志物引导医学的成像 (MRI)。所提出的 PET/MRI 系统通过将 PET 的代谢和分子信息与 MRI 的结构、功能信息相结合，将具有一些独特的优势，可以改善 AD 的早期和鉴别诊断。所提出的 PET/MRI 技术的商业化和临床使用将克服 AD 检测、干预和预防的“一刀切”方法，并将推动 AD 管理领域超越加拿大和全球目前的护理标准。